SI2316431T1 - Trdna sestava za oralno odmerjanje, ki vsebuje agonista receptorja S1P in sladkorni alkohol - Google Patents

Trdna sestava za oralno odmerjanje, ki vsebuje agonista receptorja S1P in sladkorni alkohol

Info

Publication number
SI2316431T1
SI2316431T1 SI200432283T SI200432283T SI2316431T1 SI 2316431 T1 SI2316431 T1 SI 2316431T1 SI 200432283 T SI200432283 T SI 200432283T SI 200432283 T SI200432283 T SI 200432283T SI 2316431 T1 SI2316431 T1 SI 2316431T1
Authority
SI
Slovenia
Prior art keywords
receptor agonist
sugar alcohol
oral composition
solid oral
solid
Prior art date
Application number
SI200432283T
Other languages
English (en)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Mitsubishi Pharma Coroporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2316431(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Pharma Coroporation filed Critical Novartis Ag
Publication of SI2316431T1 publication Critical patent/SI2316431T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
SI200432283T 2003-04-08 2004-04-06 Trdna sestava za oralno odmerjanje, ki vsebuje agonista receptorja S1P in sladkorni alkohol SI2316431T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
EP10184951.1A EP2316431B1 (en) 2003-04-08 2004-04-06 Solid oral composition comprising a S1P receptor agonist and a sugar alcohol

Publications (1)

Publication Number Publication Date
SI2316431T1 true SI2316431T1 (sl) 2016-04-29

Family

ID=32326722

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200432283T SI2316431T1 (sl) 2003-04-08 2004-04-06 Trdna sestava za oralno odmerjanje, ki vsebuje agonista receptorja S1P in sladkorni alkohol
SI200431037T SI1613288T1 (sl) 2003-04-08 2004-04-06 Trdni farmacevtski sestavki, ki obsegajo agonist receptorja S1P in sladkorni alkohol

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200431037T SI1613288T1 (sl) 2003-04-08 2004-04-06 Trdni farmacevtski sestavki, ki obsegajo agonist receptorja S1P in sladkorni alkohol

Country Status (42)

Country Link
US (11) US20060275357A1 (sl)
EP (5) EP2316431B1 (sl)
JP (3) JP5495467B2 (sl)
KR (3) KR20050121712A (sl)
CN (2) CN1767819B (sl)
AR (3) AR043987A1 (sl)
AT (3) ATE414508T1 (sl)
AU (1) AU2004228929B2 (sl)
BE (2) BE1015972A5 (sl)
BR (1) BRPI0409250B8 (sl)
CA (2) CA2521325C (sl)
CL (2) CL2004000745A1 (sl)
CY (3) CY1110260T1 (sl)
DE (4) DE102004016947A1 (sl)
DK (2) DK2316431T3 (sl)
EC (1) ECSP056090A (sl)
ES (3) ES2556947T3 (sl)
FR (2) FR2854073B1 (sl)
GB (1) GB2400318B (sl)
GR (1) GR1005052B (sl)
HK (3) HK1071685A1 (sl)
HR (3) HRP20050886B1 (sl)
HU (2) HUE028247T2 (sl)
IL (3) IL170888A (sl)
IS (2) IS2682B (sl)
IT (1) ITMI20040682A1 (sl)
LU (1) LU91867I2 (sl)
MA (1) MA27729A1 (sl)
MX (1) MXPA05010860A (sl)
MY (1) MY141249A (sl)
NO (4) NO329332B1 (sl)
NZ (3) NZ542622A (sl)
PE (5) PE20050396A1 (sl)
PL (2) PL2316431T3 (sl)
PT (1) PT1613288E (sl)
RU (5) RU2358716C2 (sl)
SG (1) SG175449A1 (sl)
SI (2) SI2316431T1 (sl)
TN (1) TNSN05256A1 (sl)
TW (1) TWI332847B (sl)
WO (1) WO2004089341A1 (sl)
ZA (1) ZA200507394B (sl)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010630A1 (en) * 2004-07-30 2006-02-02 Novartis Ag Compound formulations of 2-amino-1, 3-propanediol compounds
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
SI1926483T1 (sl) * 2005-09-09 2011-04-29 Novartis Ag Zdravljenje avtoimunskih bolezni
HUE034863T2 (en) 2005-11-09 2018-03-28 Onyx Therapeutics Inc Compound for inhibiting enzyme
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ603303A (en) 2006-06-19 2014-05-30 Onyx Therapeutics Inc Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
SI3103448T1 (sl) * 2006-09-26 2019-11-29 Novartis Ag Farmacevtski sestavek, ki vsebuje modulator S1P
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
BRPI0809205B8 (pt) * 2007-03-29 2021-05-25 Daiichi Sankyo Co Ltd composição farmacêutica
WO2009045497A1 (en) 2007-10-04 2009-04-09 Proteolix, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
EP3733162A1 (en) 2007-10-12 2020-11-04 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
AU2009227629B2 (en) 2008-03-17 2014-09-04 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
SG10201406263SA (en) 2008-06-20 2015-02-27 Novartis Ag Paediatric compositions for treating multiple sclerosis
WO2009152922A1 (de) * 2008-06-20 2009-12-23 Merck Patent Gmbh Direkt verpressbare und schnell zerfallende tablettenmatirx
BRPI0919183B8 (pt) * 2008-09-04 2021-05-25 Cargill Inc composição comprimível de eritritol, processo e uso do mesmo
EA035100B1 (ru) 2008-10-21 2020-04-28 Оникс Терапьютикс, Инк. Комбинированная терапия с применением пептид эпоксикетонов
CN102256933A (zh) 2008-11-11 2011-11-23 诺瓦提斯公司 芬戈莫德的盐
KR101393994B1 (ko) * 2008-11-11 2014-05-14 노파르티스 아게 핑골리모드 ｈｃｌ의 결정질 형태
AU2013100532B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
CA2747427C (en) 2008-12-17 2015-10-13 Daiichi Sankyo Company, Limited Method for producing diamine derivative
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd INHIBITOR OF AN ACTIVE FACTOR OF BLOOD COAGULATION
WO2010104078A1 (ja) 2009-03-10 2010-09-16 第一三共株式会社 ジアミン誘導体の製造方法
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
MY155256A (en) * 2009-06-18 2015-09-30 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved solubility
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
BR112012023649B1 (pt) 2010-03-19 2021-06-08 Daiichi Sankyo Company, Limited Método para produção de cristais de forma ii de monoidrato de n1 -(5-cloropiridin-2-il)-n2 -((1s,2r,4s)-4-[(dimetilamino) carbonil]-2-{[(5-metil-4,5,6,7-tetrahidrotiazol[5,4-c]piridin-2-il) carbonil] amino}ciclohexil)etanodiamida p-toluenossulfonato
KR101792299B1 (ko) 2010-03-19 2017-10-31 다이이찌 산쿄 가부시키가이샤 항응고제의 용출 개선 방법
EP2560619A2 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH A method of preparing an oral dosage form comprising fingolimod
CA2859191C (en) 2010-07-02 2016-05-17 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
EP2665471B1 (en) 2011-01-19 2017-12-27 Pathologica, LLC. Controlled release oral pharmaceutical dosage forms comprising mgbg
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
KR101940840B1 (ko) 2011-08-10 2019-01-21 다이이찌 산쿄 가부시키가이샤 디아민 유도체 함유 의약 조성물
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
UY34897A (es) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CA2896977C (en) 2013-01-08 2021-12-07 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
JP6294872B2 (ja) * 2013-04-26 2018-03-14 国立大学法人京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
WO2015015254A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
JP2018502168A (ja) * 2015-01-20 2018-01-25 ハンダ ファーマシューティカルズ エルエルシー 安定な固体フィンゴリモド剤形
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
KR100358922B1 (ko) 1994-08-22 2003-01-24 미쯔비시 웰 파마 가부시키가이샤 벤젠화합물및그의의약으로서의용도
HU224814B1 (en) 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DE69840169D1 (de) * 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
EP1319651B1 (en) * 1997-04-04 2005-06-29 Mitsubishi Pharma Corporation 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
AU8533101A (en) * 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
US7326801B2 (en) 2001-03-26 2008-02-05 Novartis Ag 2-amino-propanol derivatives
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003020313A1 (fr) 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
WO2003029184A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
ES2292809T3 (es) 2001-09-27 2008-03-16 Kyorin Pharmaceutical Co., Ltd. Derivado de sulfuro de diarilo, sal de adicion del mismo, y agente inmunosupresor.
EP1470137B1 (en) 2002-01-18 2009-09-02 Merck & Co., Inc. Edg receptor agonists
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
JP2005519915A (ja) 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
PL1772145T3 (pl) * 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym

Also Published As

Publication number Publication date
AT501681B1 (de) 2012-04-15
FR2854073B1 (fr) 2008-03-14
NO20100250L (no) 2006-01-09
DE202004021680U1 (de) 2010-04-22
SI1613288T1 (sl) 2009-04-30
KR20050121712A (ko) 2005-12-27
GR20040100121A (el) 2004-12-17
AR078781A2 (es) 2011-11-30
US20220031609A1 (en) 2022-02-03
US8324283B2 (en) 2012-12-04
NO2011016I1 (no) 2011-09-19
RU2010146697A (ru) 2012-05-27
EP2316431B1 (en) 2015-09-30
AU2004228929B2 (en) 2008-02-07
RU2010147000A (ru) 2012-08-10
HUS1100016I1 (hu) 2016-08-29
WO2004089341A1 (en) 2004-10-21
US20190175527A1 (en) 2019-06-13
CY1110260T1 (el) 2014-04-09
HK1091114A1 (en) 2007-01-12
EP2008650A2 (en) 2008-12-31
RU2475236C2 (ru) 2013-02-20
US20080311188A1 (en) 2008-12-18
JP2011006461A (ja) 2011-01-13
CN101797241A (zh) 2010-08-11
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
FR11C0036I2 (fr) 2023-12-29
SG175449A1 (en) 2011-11-28
MXPA05010860A (es) 2006-05-25
NZ542622A (en) 2009-01-31
CY2011013I1 (el) 2014-04-09
NO2011016I2 (no) 2012-08-27
PE20130200A1 (es) 2013-03-09
NO335120B1 (no) 2014-09-22
DK1613288T3 (da) 2009-03-23
JP2013177404A (ja) 2013-09-09
EP2008650A3 (en) 2011-04-27
EP1613288B1 (en) 2008-11-19
CY1117071T1 (el) 2017-04-05
KR101367574B1 (ko) 2014-02-25
DE122011100047I1 (de) 2011-12-15
MA27729A1 (fr) 2006-01-02
US20200237690A1 (en) 2020-07-30
HRP20100601A2 (hr) 2011-03-31
RU2005134173A (ru) 2006-09-10
TNSN05256A1 (en) 2007-07-10
BRPI0409250B8 (pt) 2022-01-18
RU2012148593A (ru) 2014-05-20
ES2228282A1 (es) 2005-04-01
ES2556947T3 (es) 2016-01-21
HRP20100601B1 (hr) 2016-12-02
HK1155647A1 (en) 2012-05-25
ES2320767T3 (es) 2009-05-28
RU2475237C2 (ru) 2013-02-20
ITMI20040682A1 (it) 2004-07-06
TWI332847B (en) 2010-11-11
IS8885A (is) 2010-02-25
ES2228282B1 (es) 2006-02-16
ZA200507394B (en) 2007-03-28
AR078782A2 (es) 2011-11-30
AU2004228929A1 (en) 2004-10-21
GB0407819D0 (en) 2004-05-12
FR2854073A1 (fr) 2004-10-29
EP2769713A1 (en) 2014-08-27
RU2009105403A (ru) 2010-08-27
KR20110005320A (ko) 2011-01-17
CN1767819A (zh) 2006-05-03
IL197578A (en) 2015-10-29
DE102004016947A1 (de) 2004-10-21
FR11C0036I1 (fr) 2011-10-14
IS2682B (is) 2010-10-15
IS8114A (is) 2005-11-01
US20140255497A1 (en) 2014-09-11
NO20131287L (no) 2006-01-09
CA2521325C (en) 2010-09-14
US20130108675A1 (en) 2013-05-02
NO20055231D0 (no) 2005-11-07
AT501681A1 (de) 2006-10-15
HRP20050886A2 (en) 2006-11-30
PL1613288T3 (pl) 2009-07-31
BRPI0409250A (pt) 2006-03-28
CN1767819B (zh) 2010-07-28
LU91867I2 (fr) 2011-11-08
PE20131352A1 (es) 2013-11-14
ATE414508T1 (de) 2008-12-15
EP2319502A1 (en) 2011-05-11
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
IL197578A0 (en) 2011-07-31
CY2011013I2 (el) 2014-04-09
US20110105620A1 (en) 2011-05-05
CA2707750A1 (en) 2004-10-21
US20170290787A1 (en) 2017-10-12
BRPI0409250B1 (pt) 2017-07-11
HRP20100600A2 (hr) 2011-03-31
DK2316431T3 (en) 2016-01-11
CA2521325A1 (en) 2004-10-21
TW200503784A (en) 2005-02-01
JP5495467B2 (ja) 2014-05-21
PE20090743A1 (es) 2009-07-17
JP2004307506A (ja) 2004-11-04
NO329332B1 (no) 2010-09-27
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
JP5543298B2 (ja) 2014-07-09
EP1613288A1 (en) 2006-01-11
PE20050396A1 (es) 2005-07-05
NO334116B1 (no) 2013-12-16
CL2004000745A1 (es) 2005-02-11
KR20120101148A (ko) 2012-09-12
BE2011C030I2 (sl) 2023-03-07
GB2400318A (en) 2004-10-13
NZ592339A (en) 2012-09-28
DE602004017847D1 (de) 2009-01-02
RU2358716C2 (ru) 2009-06-20
IE20040246A1 (en) 2004-12-15
AT504853A2 (de) 2008-08-15
MY141249A (en) 2010-03-31
LU91867I9 (sl) 2019-01-03
HUE028247T2 (en) 2016-12-28
US20090203798A1 (en) 2009-08-13
GB2400318B (en) 2005-08-10
US20140011885A1 (en) 2014-01-09
US20060275357A1 (en) 2006-12-07
HRP20050886B1 (en) 2011-01-31
IL242037A0 (en) 2015-11-30
PE20150676A1 (es) 2015-05-17
NZ586280A (en) 2011-12-22
AR043987A1 (es) 2005-08-17
IL170888A (en) 2010-06-16
PT1613288E (pt) 2009-02-25
GR1005052B (el) 2005-11-30
ECSP056090A (es) 2006-03-01

Similar Documents

Publication Publication Date Title
HK1155647A1 (en) Solid oral composition comprising a s1p receptor agonist and a sugar alcohol s1p
PT2277521E (pt) Formulações orais de agonistas de opióides resistentes a adulteração
IL169902A0 (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
HK1085131A1 (en) Solid drug for oral use
ZA200508733B (en) Muscarinic M1 receptor agonists for pain management
EP1701691A4 (en) METHODS AND COMPOSITIONS FOR ORAL HYGIENE
ZA200606174B (en) Multiparticulate formulations for oral delivery
EP1757273A4 (en) PREPARATION FOR ORAL ADMINISTRATION
HK1107012A1 (en) Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
IL177826A0 (en) Oral matrix formulations comprising licarbazepine
GB2391809B (en) Pharmaceutical composition comprising honey
EP1811967A4 (en) METHOD AND FORMULATIONS FOR PREPARING PHARMACEUTICAL COMPOSITIONS WITH BUPROPION
IL161997A (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
EP1755477A4 (en) MOUTH HYGIENE COMPOSITIONS AND METHOD OF USE THEREOF
AU2003252683A8 (en) Composition for oral use
IL178296A0 (en) Pharmaceutical compositions containing a gaba?? receptor agonist
GB0325383D0 (en) Oral formulations
GB2403407B (en) Palatable oral anthelmintic composition
EP1614417A4 (en) SOLID PREPARATION FOR ORAL USE
PL377147A1 (pl) Doustna kompozycja
AU2003280065A1 (en) Bupropion hydrochloride solid dosage forms
GB0406393D0 (en) Oral composition
GB0406392D0 (en) Oral composition
GB0413138D0 (en) Preparation for oral administration
AU2004900654A0 (en) Oral Hygiene Device